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1015-9584/Copyright ª 2015, Asian SuSummary Background/Objective: The concept of salvage pulmonary resection after defini-
tive chemoradiotherapy (dCRT) is not yet commonly accepted in lung cancer treatment. We
report our experience of eight patients in whom we performed salvage pulmonary resection
for residual disease or isolated locoregional recurrence detected after dCRT.
Methods: Between 2005 and 2014, we performed salvage pulmonary resection for eight pa-
tients with N2 Stage-IIIA non-small cell lung cancer. The patients had initially received dCRT
(radiation  60 Gy), but eventually underwent pulmonary resection with curative intent for
residual disease or isolated locoregional recurrence. The postoperative complications, inci-
dence of recurrence, and survival parameters were evaluated.
Results: Salvage pulmonary resection was performed in four patients with residual disease and
four patients with locoregional recurrence. Complete resection was successfully performed in
all eight patients. Postoperative complications were observed in three patients, however,
there were no postoperative mortalities. One patient developed local recurrence in a medias-
tinal lymph node and two patients died. Of the two fatalities, one was related to lung cancer.
The estimated 5-year survival rate of the eight patients was 75.0%.
Conclusion: We report our experience of salvage pulmonary resection performed for residual
disease or isolated locoregional recurrence diagnosed after dCRT in eight patients with locallyconducted without any financial support or funds and none of the authors has any financial or other
lare.
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10.1016/j.asjsur.2015.05.006advanced lung cancer. Although the postoperative complication rate was high, the survival
data were favorable. A larger study is needed to confirm the safety and feasibility of salvage
pulmonary resection after dCRT.
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reserved.1. Introduction
In patients with esophageal cancer, salvage esophagectomy
is sometimes performed after definitive chemoradiation
therapy (dCRT).1e3 Salvage esophagectomy can be defined
in two ways: (1) esophagectomy performed for isolated
locoregional recurrence developing after initial complete
response to dCRT and (2) esophagectomy performed for
residual disease detected after dCRT. Salvage esoph-
agectomy carries definite risks, but could improve outcomes
and is considered a valid therapeutic option in selected
patients with isolated locoregional recurrence or residual
disease detected after dCRT. The concept of salvage pul-
monary resection is, however, not yet common in the area of
lung cancer. We report our experience of salvage pulmonary
resection performed in eight patients with N2 Stage-IIIA non-
small cell lung cancer. The patients had initially been
treated by dCRT (radiation  60 Gy), but eventually un-
derwent pulmonary resection with curative intent for re-
sidual disease or isolated locoregional recurrence.2. Methods
Salvage pulmonary resection was defined as follows in this
study: pulmonary resection performed in patients with
pathologically proven N2 Stage-IIIA non-small cell lung
cancer who had received dCRT (radiation  60 Gy), which
was not initially intended as an induction treatment for
surgery, but who subsequently underwent pulmonary
resection with curative intent for residual disease detected
after dCRT or for isolated locoregional recurrence devel-
oping after initial complete response to dCRT. Residual
disease in this study was defined as disease that showed
good response to dCRT, but with a small amount of disease
remaining at one or two sites. Locoregional recurrence was
defined as disease developing after initial complete
response to the dCRT. The candidates for salvage pulmo-
nary resection were carefully evaluated by our Cancer
Board for pulmonary function, performance status, co-
morbidity, and curability. Between 2005 and 2014, we
performed salvage pulmonary resection in eight patients.
The clinical data of the eight patients, including tumor
histology, disease stage at diagnosis, treatments adminis-
tered before the salvage resection, time interval from the
first treatment to the salvage resection, surgical pro-
cedures employed, postoperative complications, and sur-
vival and recurrence data were analyzed. The 5-year
survival rate was calculated using JMP, version 10 (SAS
Institute Inc., Cary, NC, USA). Patients seen before 2009
were staged according to the sixth edition of the tumor,awada S, et al., Eight cases of s
chemoradiotherapy for N2 Stage-Inodes, metastases (TNM) staging system and patients seen
after 2010 were staged according to the seventh edition.
This retrospective study was conducted with the approval
of Shikoku Cancer Center hospital Internal Review Board.
3. Results
The characteristics of the eight patients who underwent
salvage pulmonary resection are listed in Table 1. All eight
patients were male and the median age was 61 years. The
initial stage was N2 Stage IIIA in all eight patients, with N2
confirmed histologically in only two patients. The treat-
ments administered before salvage resection were dCRT in
six patients and dCRT followed by second-line chemo-
therapy in two patients. In four patients, the salvage
resection was performed for residual disease, while in the
remaining four patients the salvage resection was per-
formed for isolated locoregional recurrence. A typical case
of salvage pulmonary resection is shown in Figure 1. The
primary tumor was located in the right upper lobe. Positron
emission tomography-computed tomography (PET/CT)
showed fluorine-18-deoxyglucose (FDG) accumulation in
the primary tumor, #2R, #4R, and #10R. Endobronchial
ultrasound-guided transbronchial needle aspiration (EBUS-
TBNA) revealed adenocarcinoma in #4R. This patient was
diagnosed as having T1N2M0 Stage IIIA disease and was
treated with dCRT. PET/CT after completion of the dCRT
revealed no evidence of disease in the primary tumor, #2R
or #10R, but FDG accumulation was still observed in #4R.
This patient was considered to have residual disease in #4R,
and underwent salvage pulmonary resection.
The median time interval from initial treatment
to salvage pulmonary resection was 9.4 months (3e50
months). Lobectomy was performed in four patients,
lobectomy þ pulmonary artery plasty in one patient,
lobectomy þ bronchoplasty in one patient,
lobectomy þ pulmonary artery plasty þ bronchoplasty in
one patient, and pneumonectomy in one patient. Complete
resection (R0) was achieved in all eight patients. Post-
operative complications were observed in three patients,
however, there was no postoperative mortality. Adjuvant
treatments were administered after the salvage resection
in two patients. The median follow-up period after the
salvage pulmonary resection was 48 months (range, 1.5e80
months). One patient developed mediastinal lymph node
recurrence during the follow-up period. Two patients died
during the study period, with one of these two patients
dying of lung cancer 10 months after the salvage pulmonary
resection and the other from an unknown cause. The esti-
mated 5-year survival rate from the salvage pulmonary
resection was 75.0%.alvage pulmonary resection for residual disease or isolated local
IIA lung cancer, Asian Journal of Surgery (2015), http://dx.doi.org/
Table 1 List of the eight patients.
No. Age (y) Initial T Initial N Histological
subtype
Treatments administered
before salvage
Reason for salvage Time interval
from dCRT to
salvage (mo)
1 66 1a 2 Ad CDDP þ DOC þ RT Residual disease 3.0
2 61 2a 2 SCC CDDP þ VNR þ RT Residual disease 9.4
3 62 3 2 SCC CDDP þ VNR þ RT Residual disease 9.4
4 54 1 2 SCC CDDP þ S-1 þ RT/
CDDP þ GEM
Locoregional recurrence 21.0
5 56 1 2 SCC CBDCA þ PTX þ RT/
PTX
Locoregional recurrence 49.8
6 61 1 2a Ad CDDP þ DOC þ RT Locoregional recurrence 19.7
7 57 1 2a Ad CDDP þ DOC þ RT Residual disease 3.2
8 67 2b 2 SCC CDDP þ DOC þ RT Locoregional recurrence 14.5
Extent of resection Postoperative
complication
Adjuvant
chemotherapy
pT pN Recurrence Alive or dead OS from
salvage (mo)
Lobectomy Chylothorax (Grade 2) No 1a 0 No Alive 48.2
Lobectomy þ PA plasty Pneumonia (Grade 3),
Recurrent laryngeal
nerve palsy (Grade 2)
No 1b 2 No Unknown death 1.5
Lobectomy Pleural effusion
(Grade 2)
No 3 0 Mediastinal
lymph node
Lung cancer-
related
death
10.3
Lobectomy þ PA plasty þ
bronchoplasty
None No 0 2 No Alive 78.9
Lobectomy þ
bronchoplasty
None No 2 0 No Alive 80.0
Lobectomy None CDDP þ VNR 1 2 No Alive 64.1
Lobectomy None CDDP þ VNR 1 2 No Alive 60.9
Pneumonectomy None No 1a 0 No Alive 12.1
Ad Z adenocarcinoma; CBDCA Z carboplatin; CDDP Z cisplatin; dCRT Z definitive chemoradiotherapy; DOC Z docetaxel;
GEMZ gemcitabine; OSZ overall survival; PAZ pulmonary artery; PTXZ paclitaxel; RTZ radiation; SCCZ squamous cell carcinoma;
VNR Z vinorelbine.
a N2 was confirmed histologically.
Figure 1 Images of positron emission tomography-computed tomography obtained before definitive chemoradiotherapy and
before salvage resection in a typical case. dCRT Z definitive chemoradiotherapy; OS Z overall survival.
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The concept of salvage pulmonary resection in the area
of lung cancer treatment is not yet commonly accepted
and the definitions of salvage pulmonary resection vary
among investigators. While several investigators have
reported and refer to pulmonary resection afterPlease cite this article in press as: Sawada S, et al., Eight cases of s
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investigators refer to pulmonary resection after chemo-
therapy or Iressa as salvage resection.6e8 In the field of
esophageal cancer treatment, salvage esophagectomy is
defined as esophagectomy with curative intent for re-
sidual disease or isolated locoregional recurrence diag-
nosed after dCRT.1e3,9 In this study, we applied a similaralvage pulmonary resection for residual disease or isolated local
IA lung cancer, Asian Journal of Surgery (2015), http://dx.doi.org/
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monary resection.
Diagnosis of residual disease or recurrence should be
made carefully, because it is critical to determine the in-
dications of salvage pulmonary resection appropriately. In
general, transbronchial lung biopsy, EBUS-TBNA, or CT-
guided needle biopsy are performed to obtain histological
confirmation during the process of lung cancer diagnosis.
Histological confirmation is, however, often difficult in pa-
tients with suspected residual disease or recurrence diag-
nosed after dCRT. In such cases, diagnosis of residual disease
or recurrence is usually made based on imaging findings.
Recently, it has been reported that PET/CT is useful for
prediction of response to chemotherapy and/or radiation
and that PET-CT findings are correlated with survival.10,11
PET/CT is also considered to be useful to detect recurrence
or residual disease, but its accuracy and specificity in this
regard remain unproven.12,13 In this study, the diagnosis of
residual disease or recurrence was made based on PET/CT
findings in all patients and no histological confirmation was
obtained before salvage pulmonary resection. Postoperative
histological examination revealed viable cells in all the le-
sions detected by PET/CT. Diagnosis of residual disease or
locoregional recurrence, however, shouldbecarefullymade.
Baumann et al14 reported on a series of 24 cases of
salvage pulmonary resection performed after definitive
radiation with or without chemotherapy. They reported
postoperative mortality, morbidity, and 3-year survival
rates after salvage pulmonary resection of approximately
4%, 58%, and 47%, respectively, and concluded that while
salvage pulmonary resection entailed some risk, it could
potentially offer long-term survival. Albain et al15 reported
a phase III study of induction chemoradiotherapy followed
by resection. They reported a good local control rate of as
low as 10% and a 5-year survival rate of 27%, while the
perioperative mortality rate was 8%, which was w4e8-
times as high as that of ordinary lobectomy for lung can-
cer.16e18 They concluded that pulmonary resection after
induction chemoradiotherapy improved overall survival,
with a lower incidence of local recurrence and acceptable
mortality. By contrast, a standard treatment for residual
disease or locoregional recurrence after dCRT is chemo-
therapy. The reported response rate to chemotherapy in
patients with a previous history of chemotherapy is only
w10%, and the efficacy of this treatment is limited.19,20
Cure can rarely be expected from chemotherapy treat-
ment in patients with residual disease or isolated locore-
gional recurrence diagnosed after dCRT. Considering these
issues, salvage pulmonary resection in patients with resid-
ual disease or locoregional recurrence after dCRT could be
taken into consideration, provide good local control, and
potentially offer longer-term survival.
Regarding locoregional recurrence, salvage pulmonary
resection was performed in those patients who had initially
shown complete response to dCRT and developed only
locoregional recurrence without distant metastasis. The
tumor behavior in such patients was considered to be less
aggressive and had a tendency to remain localized, there-
fore, the outcome of salvage resection in this patient
population was expected to be good. In patients with re-
sidual disease, salvage pulmonary resection was performed
only in patients who showed good response to dCRT and hadPlease cite this article in press as: Sawada S, et al., Eight cases of s
recurrence detected after definitive chemoradiotherapy for N2 Stage-I
10.1016/j.asjsur.2015.05.006residual disease in only one or two sites. In studies of in-
duction chemoradiotherapy followed by surgery, patients
with good response, stable disease, and progressive disease
have been evaluated together based on the rule of intent to
treatment. Outcomes, however, would be better if only
patients who showed good response to induction chemo-
radiotherapy were selected and evaluated. The patients
with residual disease in this study are considered to be
similar to patients who showed good response to induction
chemoradiotherapy. These characteristics may explain the
good 5-year survival rate of salvage pulmonary resection
observed in this study.
This study has some distinct limitations. Diagnosis of N2
was confirmed histologically in only two patients and was
determined based on imaging findings, including findings
using PET/CT, in the remaining six patients. A doubt was
raised in this study concerning whether the initial N2
diagnosis was accurate. The study was retrospective in
nature, based on clinical records, and this limitation is al-
ways involved. The other issue might involve the small
sample size of eight patients. Many of our patients who
underwent dCRT for N2 Stage-IIIA disease developed distant
metastasis after dCRT, with only a few developing locore-
gional recurrences without distant metastasis. Regarding
residual disease, salvage pulmonary resection was per-
formed in this study only in patients who showed good
response to dCRT, with residual disease remaining in only
one or two sites. Moreover, salvage pulmonary resection
was performed only in healthy patients and not in patients
with a poor performance status and organ dysfunction,
even if the patients had only resectable disease. Thus,
candidates for salvage pulmonary resection are considered
to be very limited and only eight patients were, therefore,
identified as suitable candidates for salvage pulmonary
resection during the 10-year period. It is difficult to eval-
uate the safety and feasibility of salvage pulmonary
resection after dCRT from the results of this study, since
this study was retrospective in nature and the sample size
was too small. Therefore, a large and ideally prospective
study is needed to confirm our findings.
In conclusion, we report the eight cases of salvage
pulmonary resection performed for residual disease or
isolated locoregional recurrence diagnosed after dCRT.
The postoperative complication rate was high, although
the survival data were favorable. A larger study is needed
to evaluate the feasibility of salvage pulmonary resection
after dCRT.References
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